IN2012DN06631A - - Google Patents

Info

Publication number
IN2012DN06631A
IN2012DN06631A IN6631DEN2012A IN2012DN06631A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A IN 6631DEN2012 A IN6631DEN2012 A IN 6631DEN2012A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A
Authority
IN
India
Prior art keywords
yloxy
methyl
isoxazol
pyran
piperidin
Prior art date
Application number
Other languages
English (en)
Inventor
Hirohide Noguchi
Nobuaki Waizumi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN06631A publication Critical patent/IN2012DN06631A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN6631DEN2012 2010-02-16 2011-02-09 IN2012DN06631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (en) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Publications (1)

Publication Number Publication Date
IN2012DN06631A true IN2012DN06631A (pt) 2015-10-23

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6631DEN2012 IN2012DN06631A (pt) 2010-02-16 2011-02-09

Country Status (15)

Country Link
US (1) US20120041026A1 (pt)
EP (1) EP2536713A1 (pt)
JP (1) JP2013519722A (pt)
KR (1) KR20120123089A (pt)
CN (1) CN102762554A (pt)
AR (1) AR080172A1 (pt)
AU (1) AU2011216950A1 (pt)
CA (1) CA2788656A1 (pt)
IN (1) IN2012DN06631A (pt)
MX (1) MX2012008721A (pt)
SG (1) SG183111A1 (pt)
TW (1) TW201141856A (pt)
UY (1) UY33225A (pt)
WO (1) WO2011101774A1 (pt)
ZA (1) ZA201206469B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
BR112013029319A2 (pt) 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4
CA2890861C (en) * 2012-11-21 2021-03-30 Raqualia Pharma Inc. Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
US9790211B2 (en) 2013-03-20 2017-10-17 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
JP6161823B2 (ja) 2013-12-16 2017-07-12 スヴェン・ライフ・サイエンシズ・リミテッド 5−ht4受容体アゴニストとしてのインダゾール化合物
US9988370B2 (en) * 2014-05-20 2018-06-05 Raqualia Pharma Inc. Benzisoxazole derivative salt
ES2734734T3 (es) 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660969B2 (en) 1991-02-27 1995-07-13 Merrell Pharmaceuticals Inc. NMDA antagonists
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
JP3462501B2 (ja) * 1992-11-23 2003-11-05 アベンティス・ファーマスーティカルズ・インコーポレイテツド 置換された3−(アミノアルキルアミノ)−1,2−ベンゾイソキサゾールおよび関連化合物
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
PL186781B1 (pl) 1995-09-29 2004-02-27 Glaxo Wellcome Spa Nowy związek, pochodna tetrahydrochinoliny, sposób wytwarzania pochodnej tetrahydrochinoliny, środek farmaceutyczny i zastosowanie
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
WO1997038993A1 (en) 1996-04-12 1997-10-23 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
KR20000022380A (ko) 1996-07-01 2000-04-25 둘락 노먼 씨. 무스카린 길항제
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
IL129187A0 (en) 1996-09-30 2000-02-17 Hoechst Marion Roussel Inc NMDA (N-methyl-D-aspartate) antagonists
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
DE60223904T2 (de) 2001-01-26 2008-11-27 Btg International Ltd. Benzylaminanalogen
AU2002250256B2 (en) 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
ATE403651T1 (de) 2003-06-04 2008-08-15 Merck & Co Inc 3-fluoro-piperidine als nmda/nr2b antagonisten
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
EP1809604A1 (en) 2004-10-15 2007-07-25 Universidade Federal Do Rio De Janeiro - UFRJ Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
WO2007016357A1 (en) 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
CN101437510B (zh) 2006-03-20 2012-12-05 科学与工业研究会 用作乙酰胆碱酯酶抑制剂的药物组合物
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
AU2007336219A1 (en) 2006-12-20 2008-06-26 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
EP2522667B1 (en) 2007-05-01 2014-08-20 Concert Pharmaceuticals Inc. Morphinan compounds
WO2008138200A1 (en) 2007-05-11 2008-11-20 Hong Kong University Of Science & Technology Nmda and mc receptor antagonists exhibiting neuroprotective and memory enhancing activities
CN103497114A (zh) 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
AP2010005217A0 (en) 2007-09-12 2010-04-30 Virginia Tech Intell Prop Insecticidal carbamates exhibiting species-selective inhibition of acetyl cholinesterase (ACHE)
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
WO2009137843A2 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
SG183111A1 (en) 2012-09-27
UY33225A (es) 2011-09-30
KR20120123089A (ko) 2012-11-07
EP2536713A1 (en) 2012-12-26
JP2013519722A (ja) 2013-05-30
TW201141856A (en) 2011-12-01
MX2012008721A (es) 2012-08-17
AR080172A1 (es) 2012-03-21
CN102762554A (zh) 2012-10-31
US20120041026A1 (en) 2012-02-16
WO2011101774A1 (en) 2011-08-25
ZA201206469B (en) 2013-05-29
AU2011216950A1 (en) 2012-08-23
CA2788656A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
IN2012DN06631A (pt)
MX2011010223A (es) Despliegue de juego de casino que se puede vestir y sistema de rastreo.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
BR112012031620A2 (pt) atm acessível para deficiente físico
TW200720693A (en) A comfortable ophthalmic device and methods of its production
SG176656A1 (en) Microorganisms for the production of 1,4-butanediol and related methods
MX2009005212A (es) Antagonistas del receptor de progesterona.
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
CO6551692A2 (es) Nebulizador
GB2481565A (en) Screen capture
MX2014014339A (es) Metodos y composiciones para modular la expresion de apolipoproteina (a).
MX362362B (es) Pilar dental para el soporte de protesis dentales y metodo de fabricacion del mismo.
NZ603625A (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
MX2010010345A (es) Composiciones oftalmicas topicas mejoradas.
WO2011069095A3 (en) Stuttering reduction method and device
MY156946A (en) Composition for decreasing hardness of water
AU335070S (en) Integrated winchhead
EP2580229A4 (en) D5 desaturase-defective mutant gene and use thereof
IN2014CN00817A (pt)
TWM385327U (en) Automatic body temperature measuring device and equipment
IN2014CN00834A (pt)
WO2009120381A3 (en) Faucet system and advertising method